Expert Insights
The Emerging Role of Minimal Residual Disease Testing in Hematologic Malignancies
Release Date: June 16, 2021
Expiration Date: June 15, 2022
CE/CME Credit Hours: 1.00
Pharmacology Credit Hours: 1.00
Begin »
Program Overview
Program Description
In clinical trials and clinical practice, a goal of cancer therapy is for patients to achieve a partial response or complete response to treatment. While these terms are clinically useful, they do not reflect the entire picture, and defining a response as complete may give a patient the false impression that their disease is cured. However, many patients with hematologic cancer who achieve complete response have low levels of residual malignant cells. Residual cells can ultimately lead to a relapse months to years later, so the quantification of measurable residual disease (MRD) is increasingly important to assess patient prognosis and inform treatment decisions. In this activity, Aaron C. Logan, MD, PhD, discusses the increasingly important role of testing for MRD in patients with hematologic malignancies, particularly acute lymphocytic leukemia (ALL), as a prognostic factor to help guide treatment decisions.
Format
eNewsletter with interactive benchmarking and audio commentary
Learning Objectives
After completing this activity, participants should be better able to:
- Identify the role in clinical practice of MRD testing in hematologic malignancies
- Summarize the types of MRD testing for patients with hematologic malignancies
- Describe evidence for the impact of MRD test results in patients with ALL, chronic lymphocytic leukemia, and multiple myeloma
Target Audience
Oncology NPs, PAs, and nurses
Faculty
Aaron C. Logan, MD, PhD
- Associate Professor
- Division of Hematology, Blood and Marrow Transplantation
- University of California, San Francisco
- San Francisco, California
Details
Joint Accreditation Statement
In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
NP course advisor: Kimberly Noonan, DNP, ANP-BC, Dana Farber Cancer Institute, Boston, Massachusetts
Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit
AAPA Credit Designation
Practicing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until June 15, 2022. PAs should only claim credit commensurate with the extent of their participation.
PA course advisor: Corinne Williams, PA-C, Northwestern University Feinberg School of Medicine, Chicago, Illinois
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.
This activity is supported by an educational grant from Adaptive Biotechnologies Corporation and Bristol Myers Squibb Company.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose to the audience all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Dr Logan: contracted research: Amphivena, Autolus, Jazz, Kadmon, Pharmacyclics; consulting fees: Amgen, Bristol Myers Squibb, Pfizer.
Ms Williams: consulting/speakers bureau: AbbVie, AstraZeneca.
None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose, except Ms Williams as noted above.
Participants wishing to earn CE/CME credit must:
- Read the content in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 67%.
The estimated time to complete this activity is 1.00 hour.
Release date: June 16, 2021
Expiration date: June 15, 2022
For Practicing Clinicians Exchange general information, contact pce@practicingclinicians.com.
© 2022 Practicing Clinicians Exchange. All Rights Reserved. 102421B